Javier Hornedo

1.7k total citations
53 papers, 1.2k citations indexed

About

Javier Hornedo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Javier Hornedo has authored 53 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in Javier Hornedo's work include Cancer Treatment and Pharmacology (15 papers), Neutropenia and Cancer Infections (15 papers) and Hematopoietic Stem Cell Transplantation (7 papers). Javier Hornedo is often cited by papers focused on Cancer Treatment and Pharmacology (15 papers), Neutropenia and Cancer Infections (15 papers) and Hematopoietic Stem Cell Transplantation (7 papers). Javier Hornedo collaborates with scholars based in Spain, United States and Belgium. Javier Hornedo's co-authors include H. Cortés-Funes, Rámón Colomer, Manuel Hidalgo, Rocio García‐Carbonero, Carlos Lumbreras, José Trigo, Mario A. Eisenberger, Ross C. Donehower, Monica B. Spaulding and David Van Echo and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Javier Hornedo

51 papers receiving 1.2k citations

Peers

Countries citing papers authored by Javier Hornedo

Since Specialization

Citations

This map shows the geographic impact of Javier Hornedo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javier Hornedo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javier Hornedo more than expected).

Fields of papers citing papers by Javier Hornedo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Javier Hornedo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javier Hornedo. The network helps show where Javier Hornedo may publish in the future.

Co-authorship network of co-authors of Javier Hornedo

This figure shows the co-authorship network connecting the top 25 collaborators of Javier Hornedo. A scholar is included among the top collaborators of Javier Hornedo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Javier Hornedo. Javier Hornedo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement 2023 ·EClinicalMedicine ·Rámón Colomer, Jesús Miranda, Nuria Romero-Laorden, Javier Hornedo, Lucía González‐Cortijo, Silvana Mourón, María J. Bueno, Rebeca Mondéjar, Miguel Quintela-Fandiño	24
2	Impact of 68Ga-PSMA PET/CT in the treatment of prostate cancer: Initial experience in Spain 2020 ·Reports of Practical Oncology & Radiotherapy ·Felipe Couñago, Claudio Martínez‐Ballesteros, Carlos Artigas, (unknown), (unknown), (unknown), (unknown), Manuel Recio, (unknown), Israel J. Thuissard, Cristina Andreu‐Vázquez, David Sanz‐Rosa, Antonio J. Conde-Moreno, (unknown), (unknown), Juan Ignacio Martínez‐Salamanca, Joaquı́n Carballido, Javier Hornedo, (unknown)	3
3	Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition 2019 ·Breast Cancer Research ·Miguel Quintela-Fandiño, (unknown), (unknown), Silvana Mourón, Javier Hornedo, Lucía González‐Cortijo, Rámón Colomer, Juan Antonio Guerra	20
4	Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers 2018 ·Annals of Oncology ·Miguel Quintela-Fandiño, (unknown), Élise Martin, Manuel Moreno, Serafín Morales, B. Bermejo De Las Heras, (unknown), Rámón Colomer, Lucía González Cortijo, Javier Hornedo, Silvana Mourón, Manuel Muñoz, (unknown), Roberto Blanco Sequeiros, Santos Mañes	5
5	Vitamin E protects against the mitochondrial damage caused by cyclosporin A in LLC-PK1 cells 2009 ·Toxicology and Applied Pharmacology ·Gabriel de Arriba, Javier Hornedo, Sara Rubio, (unknown), (unknown), (unknown), (unknown)	31
6	Flow cytometric analysis of the in situ hybridization of cyclooxygenase isoforms in mesangial cells treated with cyclosporine A 2006 ·Cytometry Part A ·Javier Hornedo, (unknown), Gabriel de Arriba, Pravina Fernandez, (unknown), (unknown)	1
7	Randomized Study of Cefepime versus Ceftazidime plus Amikacin in Patients with Solid Tumors Treated with High Dose Chemotherapy (HDC) and Peripheral Blood Stem Cell Support (PBSCS) with Febrile Neutropenia 2006 ·Clinical & Translational Oncology ·Antonio Jimeno, Alberto Arcediano, Susana Bezares, María L. Amador, Lucía González‐Cortijo, Eva Ciruelos, Luis Robles, Daniel Castellano, (unknown), Carlos Lumbreras, Javier Hornedo, (unknown)	4
8	Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: efficacy and correlation with HER2 extracellular domain 2006 ·Clinical & Translational Oncology ·Rámón Colomer, Antonio Llombart‐Cussac, Ignasi Tusquets, Juli Rifà, José Mayordomo, B. Ojeda, Eva Ciruelos, Javier Hornedo, David Vicente, H. Cortés-Funes	9
9	Cancer-Related Anemia: Pathogenesis, Prevalence and Treatment 2005 ·Oncology ·Gunnar Birgegård, Matti Aapro, Carsten Bokemeyer, Mario Dicato, P. Drings, Javier Hornedo, Maciej Krzakowski, Heinz Ludwig, S. Pecorelli, Hans‐Joachim Schmoll, M. Schneider, Dirk Schrijvers, Daniel Shasha, (unknown)	164
10	Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma 2004 ·Cancer ·Antonio Jimeno, María L. Amador, Lucía González‐Cortijo, (unknown), Santiago Ropero, (unknown), Javier Hornedo, H. Cortés-Funes, Rámón Colomer	12
11	The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period 2002 ·Bone Marrow Transplantation ·Javier Hornedo, C. Solà, Carlos Solano, (unknown), S. Alonso, Aňa Lluch, B. Ojeda, J Garcı́a-Conde, H. Cortés-Funes, (unknown)	35
12	Sequential analysis of CD34+ and CD34− cell subsets in peripheral blood and leukapheresis products from breast cancer patients mobilized with SCF plus G-CSF and cyclophosphamide 2001 ·Leukemia ·Pablo Menéndez, Felipe Prósper, Clara Bueno, Cristina Arbona, Jesús F. San Miguel, J Garcı́a-Conde, Christophe Sola, Javier Hornedo, H. Cortés-Funes, (unknown)	23
13	Granulocyte Colony-Stimulating Factor in the Treatment of High-Risk Febrile Neutropenia: a Multicenter Randomized Trial 2001 ·JNCI Journal of the National Cancer Institute ·Rocio García‐Carbonero, José Mayordomo, (unknown), M. López-Brea, (unknown), (unknown), Alberto Arcediano, Alfonso Yubero, (unknown), (unknown), A. Trés, José Luis Perez‐Gracia, Carlos Lumbreras, Javier Hornedo, H. Cortés-Funes, (unknown)	121
14	High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trial 2001 ·Bone Marrow Transplantation ·José Luis Perez‐Gracia, Rámón Colomer, Ana Ruiz‐Casado, Alberto Arcediano, (unknown), Carlos Gómez-Martín, (unknown), C. Mendiola, H. Cortés-Funes, Javier Hornedo	4
15	Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response 1999 ·British Journal of Cancer ·Eduardo Reyes, (unknown), (unknown), Javier Hornedo, H. Cortés-Funes, (unknown), (unknown)	28
16	Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis 1999 ·Journal of Antimicrobial Chemotherapy ·Sofía Perea, (unknown), Alberto Arcediano, (unknown), Carlos F. Gómez, Javier Hornedo, Carlos Lumbreras, María Dolores Folgueira, H. Cortés-Funes, (unknown)	23
17	Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. 1997 ·Journal of Clinical Oncology ·Rocio García‐Carbonero, Manuel Hidalgo, Luis Paz‐Ares, Julia Calzas, Henry Gómez, Juan Antonio Guerra, Ricardo Hitt, Javier Hornedo, Rámón Colomer, H. Cortés-Funes	68
18	The role of high dose chemotherapy in adult solid tumours other than breast cancer 1996 ·Annals of Oncology ·Javier Hornedo, (unknown)	6
19	Rhabdomyosarcoma presenting with diffuse bone marrow involvement, hypercalcemia and renal failure 1988 ·Medical and Pediatric Oncology ·Javier de la Serna, Miguel Ángel Martínez, (unknown), Javier Hornedo, (unknown), José Morales	11
20	[Extramedullary IgD lambda plasmacytoma mimicking a pituitary chromophobe adenoma]. 1983 ·PubMed ·Javier Hornedo, (unknown), (unknown), G. Aragón, (unknown), (unknown), (unknown)	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact